From light to color or new therapeutic strategy for vitiligo


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the modern concept of the treatment of vitiligo, the approaches to the choice of the optimal therapeutic algorithm, ways of assessing the clinical response; also, clinical experience of the authors is reviewed. One case report is discussed in detail. Vitiligo -the most frequent dermatosis from the group of diseases associated with the violation of skin pigmentation. The prevalence of vitiligo in the general population is 1-3%, regardless of gender. The study found that the combined use of needling techniques and NB-UVB (311 nm, TL01) allows achieving repigmentation of lesions in patients with vitiligo in the majority of cases (89.47%).

Full Text

Restricted Access

About the authors

D. V Zaslavsky

SPbSPMU

Department of Dermatovenereology

S. V Skrek

NWSMU n.a. I.I. Mechnikov; French Clinic of Skin Diseases n.a. Pierre Wolkenstein

Teaching Assistant at the Department of Dermatovenereology

A. V Sobolev

SRI of Medical Mycology n.a. P.N. Kashkin NWSMU n.a. I.I. Mechnikov

A. A Yunovidova

NWSMU n.a. I.I. Mechnikov

Department of Dermatovenereology

P. Wolkenstein

Dermatological Service of the Henri Mondor University Hospital

A. K Sydikov

SPbSPMU

Department of Dermatovenereology

A. K Kovalchuk

Dermatovenerologic Dispensary of the Central District of St. Petersburg №11

L. R Chernova

SPbSU

Department of Infectious Diseases, Epidemiology and Dermatovenereology

Yu. G Kovalchuk

French Clinic of Skin Diseases n.a. Pierre Wolkenstein

A. N Kuliyeva

NWSMU n.a. I.I. Mechnikov

Department of Dermatovenereology

References

  1. Hamzavi I., Jain H., McLean D., Shapiro J., Zeng H., Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo, using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch. Dermatol. 2004; 140:677-83.
  2. Wong P.C., Leung Y.Y., Li E.K., Tam L.S. Measuring disease activity in psoriatic arthritis. Int. J. Rheumatol. 2012;2012:839425.
  3. Taïeb A., Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20:27-35.
  4. Njoo M.D., Das P.K., Bos J.D., Westerhof W. Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch. Dermatol. 1999;135:407-13.
  5. Wakefield P.E., James W.D., Samlaska C.P., Meltzer M.S. Tumor necrosis factor. J. Am. Acad. Dermatol. 1991;24:675-85.
  6. Vassali P. The pathophysiology of tumour necrosis factor. Annu. Rev. Immunol 1992;10:411-52.
  7. Aggarwal B.B. Signaling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 2003;3:745-56.
  8. Black R.A., Rauch C.T., Kozlosky C.T., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997; 385:729-33.
  9. MacEwan D.J. TNF receptor subtype signaling: differences and ceiiuiar consequences. Ceii Signal. 2002;14:477-92.
  10. Vandenabeeie P., Deciercq W., Beyaerte R., Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Ceii Bioi. 1995;5:392-99.
  11. Nagata S., Goistein P. The Fas death factor. Science. 1995;267:1449-56.
  12. McCoy M.K., Tansey M.G. TNF signaiing inhibition in the CNS: impiications for normai brain function and neurodegenerative disease. J. Neuroinfiammation. 2008;5:45.
  13. Faustman D., Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 2010;9:482-93.
  14. Faustman D.L., Davis M. TNF receptor 2 and disease: autoimmunity and regenerative medicine. Front. Immunoi. 2013;4:1-8.
  15. Grinberg-Bieyer Y., Saadoun D., Baeyens A., Biiiiard F., Goidstein J.D., Grégoire S., Martin G.H., Eihage R., Derian N., Carpentier W., Marodon G., Kiatzmann D., Piaggio E., Saiomon B.L. Pathogenic T. ceiis have a paradoxicai protective effect in murine autoimmune diabetes by boosting Tregs. J. Ciin. Invest. 2010;120:4558-68.
  16. Biton J., Semerano L., Deiavaiiee L., Lemeiter D., Laborie M., Grouard-Vogei G., Boissier M.C., Bessis N. Interpiay between TNF and reguiatory T ceiis in a TNF-driven murine modei of arthritis. J. Immunoi. 2011;186:3899-910.
  17. Biton J., Boissier M.C., Bessis N. TNF-aipha: activator or inhibitor of reguiatory T ceiis? Joint Bone Spine. 2012;79:119-23.
  18. Bianco P., Paiucka A.K., Pascuai V., Banchereau J. Dendritic ceiis and cytokines in human infiammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19:41-52.
  19. Kroll T.M., Bommiasamy H., Boissy R.E., Hernandez C., Nickoloff B.J., Mestril R., Caroline Le Poole I. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J. Invest. Dermatol. 2005;124:798-806.
  20. Le Poole I.C., van den Wijngaard R.M., Westerhof W., Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am. J. Pathol.1996;148:1219-28.
  21. Wankowicz-Kalinska A., vanden Wijngaard R.M., Tigges B.J., Westerhof W., Ogg G.S., Cerundolo V., Storkus W.J., Das P.K. Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab. Invest. 2003;83:683-95.
  22. Chatterjee S., Eby J.M., Al-Khami A.A., Soloshchenko M., Kang H.K., Kaur N., Naga O.S., Murali A., Nishimura M.I., Le Poole I.C., Mehrotra S. A quantitative increase in regulatory T cells controls development of vitiligo. J. Invest. Dermatol. 2014;134:1285-94.
  23. Scheurich P., Thoma B., Ricer U., Pfizenmaier K. I mmunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J. Immunol. 1987; 138:1786-90.
  24. Ada S., Sahin S., Boztepe G., Karaduman A., Kölemen F. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol. Photoimmunol. Photomed. 2005;21(2):79-83.
  25. Tahir Jamii A., Tariq R., Zahida R. Needling: an adjunct to narrowband ultraviolet B therapy in localized fixed vitiligo. J. Pak. Assoc. Dermatol. 2008;18:149-53.
  26. Grimes P.E. Vitiligo: an overview of therapeutic approaches. Dermatol. Clin. 1993;11:325-28.
  27. Westerhof W., Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch. Dermatol. 1997;133:1525-28.
  28. Gawkrodger, D.J., Ormerod A.D., Shaw L., Mauri-Sole I., Whitton M.E., Watts M.J., Anstey A.V., Ingham J., Young K.; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists; Clinical Standards Department, Royal College of Physicians of London; Cochrane Skin Group; Vitiligo Society. Guideline for the diagnosis and management of vitiligo. Br. J. Dermatol. 2008;159(5):1051-76.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies